| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sweden | 418 | 2024 | 1379 | 8.520 |
Why?
|
| Nasopharyngeal Neoplasms | 26 | 2024 | 290 | 4.680 |
Why?
|
| Prostatic Neoplasms | 127 | 2024 | 11118 | 2.870 |
Why?
|
| Breast Neoplasms | 213 | 2024 | 21012 | 2.790 |
Why?
|
| Early Detection of Cancer | 27 | 2024 | 3201 | 2.200 |
Why?
|
| Neoplasms | 111 | 2024 | 22164 | 2.160 |
Why?
|
| Mass Screening | 55 | 2023 | 5428 | 2.090 |
Why?
|
| Colorectal Neoplasms | 46 | 2024 | 6935 | 1.920 |
Why?
|
| Case-Control Studies | 204 | 2024 | 22168 | 1.770 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2024 | 612 | 1.750 |
Why?
|
| Risk Factors | 399 | 2024 | 74167 | 1.740 |
Why?
|
| Lymphoma, Non-Hodgkin | 29 | 2022 | 1374 | 1.720 |
Why?
|
| Prostatectomy | 20 | 2024 | 1824 | 1.640 |
Why?
|
| Registries | 129 | 2024 | 8223 | 1.610 |
Why?
|
| Uterine Cervical Neoplasms | 35 | 2024 | 2019 | 1.590 |
Why?
|
| Parity | 46 | 2024 | 927 | 1.560 |
Why?
|
| Incidence | 169 | 2024 | 21341 | 1.450 |
Why?
|
| Epidemiology | 10 | 2012 | 279 | 1.430 |
Why?
|
| Endometrial Neoplasms | 26 | 2021 | 1365 | 1.390 |
Why?
|
| Middle Aged | 579 | 2024 | 220826 | 1.360 |
Why?
|
| Watchful Waiting | 11 | 2024 | 491 | 1.330 |
Why?
|
| Humans | 946 | 2024 | 761423 | 1.280 |
Why?
|
| Gastrointestinal Neoplasms | 7 | 2022 | 954 | 1.270 |
Why?
|
| Cohort Studies | 205 | 2024 | 41446 | 1.260 |
Why?
|
| Life Style | 39 | 2021 | 3914 | 1.230 |
Why?
|
| Colonoscopy | 19 | 2024 | 1394 | 1.220 |
Why?
|
| Diet | 51 | 2024 | 8074 | 1.190 |
Why?
|
| Norway | 39 | 2019 | 498 | 1.170 |
Why?
|
| Carcinoma in Situ | 20 | 2018 | 791 | 1.160 |
Why?
|
| Mammography | 21 | 2020 | 2430 | 1.150 |
Why?
|
| Risk | 123 | 2023 | 9612 | 1.140 |
Why?
|
| Female | 659 | 2024 | 392581 | 1.140 |
Why?
|
| Alcohol Drinking | 33 | 2021 | 4027 | 1.140 |
Why?
|
| Aged | 429 | 2024 | 169235 | 1.110 |
Why?
|
| Adult | 499 | 2024 | 221148 | 1.100 |
Why?
|
| Colonic Polyps | 7 | 2024 | 554 | 1.100 |
Why?
|
| Prostate-Specific Antigen | 24 | 2024 | 2469 | 1.100 |
Why?
|
| Body Mass Index | 61 | 2024 | 12951 | 1.080 |
Why?
|
| Smoking | 54 | 2022 | 9052 | 1.080 |
Why?
|
| Odds Ratio | 91 | 2022 | 9645 | 1.050 |
Why?
|
| Ampulla of Vater | 3 | 2024 | 149 | 1.050 |
Why?
|
| Tea | 6 | 2023 | 288 | 1.040 |
Why?
|
| Menopause | 33 | 2024 | 1646 | 1.010 |
Why?
|
| Carcinogens | 11 | 2009 | 451 | 1.010 |
Why?
|
| Estrogens | 34 | 2018 | 1522 | 1.000 |
Why?
|
| Diabetes Complications | 14 | 2012 | 1315 | 1.000 |
Why?
|
| Ranitidine | 2 | 2022 | 34 | 0.990 |
Why?
|
| Adenoma | 13 | 2024 | 2160 | 0.990 |
Why?
|
| Testicular Neoplasms | 16 | 2019 | 799 | 0.990 |
Why?
|
| Proportional Hazards Models | 78 | 2024 | 12456 | 0.980 |
Why?
|
| Male | 459 | 2024 | 360736 | 0.910 |
Why?
|
| Coffee | 8 | 2023 | 593 | 0.900 |
Why?
|
| Duodenal Neoplasms | 1 | 2024 | 114 | 0.890 |
Why?
|
| Denmark | 30 | 2023 | 771 | 0.890 |
Why?
|
| Follow-Up Studies | 150 | 2024 | 39117 | 0.870 |
Why?
|
| Premenopause | 19 | 2024 | 1039 | 0.870 |
Why?
|
| Polymorphism, Single Nucleotide | 57 | 2024 | 15941 | 0.860 |
Why?
|
| China | 32 | 2023 | 2366 | 0.860 |
Why?
|
| Age Factors | 132 | 2021 | 18400 | 0.840 |
Why?
|
| Acrylamide | 7 | 2017 | 59 | 0.840 |
Why?
|
| Hodgkin Disease | 14 | 2019 | 1378 | 0.830 |
Why?
|
| Papillomaviridae | 17 | 2015 | 1119 | 0.830 |
Why?
|
| Body Size | 9 | 2019 | 463 | 0.810 |
Why?
|
| Twins, Dizygotic | 8 | 2019 | 236 | 0.810 |
Why?
|
| Papillomavirus Infections | 18 | 2024 | 1610 | 0.800 |
Why?
|
| Feeding Behavior | 17 | 2021 | 3187 | 0.790 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2022 | 46 | 0.790 |
Why?
|
| Twins, Monozygotic | 9 | 2022 | 470 | 0.780 |
Why?
|
| Tobacco, Smokeless | 5 | 2016 | 133 | 0.780 |
Why?
|
| Kidney Neoplasms | 25 | 2023 | 4248 | 0.780 |
Why?
|
| Genetic Predisposition to Disease | 54 | 2023 | 17912 | 0.760 |
Why?
|
| Carcinoma, Renal Cell | 19 | 2012 | 3163 | 0.760 |
Why?
|
| Obesity | 38 | 2023 | 12938 | 0.740 |
Why?
|
| Sunlight | 6 | 2014 | 337 | 0.740 |
Why?
|
| Contraceptives, Oral | 20 | 2017 | 554 | 0.730 |
Why?
|
| Risk Assessment | 67 | 2024 | 23990 | 0.730 |
Why?
|
| Prospective Studies | 131 | 2024 | 54415 | 0.730 |
Why?
|
| Postmenopause | 27 | 2018 | 2513 | 0.720 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2024 | 509 | 0.720 |
Why?
|
| Europe | 29 | 2022 | 3423 | 0.710 |
Why?
|
| Histamine H2 Antagonists | 2 | 2021 | 166 | 0.710 |
Why?
|
| Herpesvirus 4, Human | 10 | 2024 | 1079 | 0.700 |
Why?
|
| Maternal Age | 22 | 2018 | 809 | 0.700 |
Why?
|
| Tumor Virus Infections | 11 | 2012 | 438 | 0.690 |
Why?
|
| Biliary Tract Neoplasms | 5 | 2023 | 185 | 0.690 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 12 | 2014 | 416 | 0.680 |
Why?
|
| Vaginal Smears | 17 | 2018 | 499 | 0.670 |
Why?
|
| Epidemiologic Studies | 13 | 2015 | 675 | 0.670 |
Why?
|
| Pancreatic Neoplasms | 13 | 2024 | 5365 | 0.660 |
Why?
|
| Age Distribution | 24 | 2021 | 2880 | 0.650 |
Why?
|
| Duodenal Ulcer | 23 | 2007 | 121 | 0.650 |
Why?
|
| Mortality | 15 | 2023 | 2900 | 0.640 |
Why?
|
| Lymphoma, Follicular | 8 | 2014 | 457 | 0.640 |
Why?
|
| Leisure Activities | 10 | 2023 | 308 | 0.640 |
Why?
|
| Ovarian Neoplasms | 24 | 2019 | 4876 | 0.630 |
Why?
|
| Estrogen Replacement Therapy | 17 | 2019 | 1208 | 0.630 |
Why?
|
| Lymphoma | 9 | 2023 | 1901 | 0.620 |
Why?
|
| Population Surveillance | 22 | 2019 | 2597 | 0.620 |
Why?
|
| Neoplasms, Second Primary | 5 | 2024 | 1051 | 0.620 |
Why?
|
| Insulin-Like Growth Factor I | 13 | 2010 | 1931 | 0.600 |
Why?
|
| Sigmoidoscopy | 6 | 2024 | 151 | 0.590 |
Why?
|
| Gallbladder Neoplasms | 6 | 2024 | 189 | 0.590 |
Why?
|
| Academies and Institutes | 2 | 2022 | 318 | 0.570 |
Why?
|
| Bile Duct Neoplasms | 7 | 2024 | 605 | 0.570 |
Why?
|
| Carcinoma | 16 | 2017 | 2330 | 0.560 |
Why?
|
| Progestins | 13 | 2018 | 301 | 0.560 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2014 | 702 | 0.560 |
Why?
|
| Multivariate Analysis | 60 | 2018 | 12058 | 0.560 |
Why?
|
| Alcoholism | 11 | 2003 | 1973 | 0.560 |
Why?
|
| Birth Weight | 23 | 2014 | 2100 | 0.550 |
Why?
|
| Cardiovascular Diseases | 29 | 2024 | 15498 | 0.550 |
Why?
|
| Metronidazole | 1 | 2018 | 232 | 0.550 |
Why?
|
| Caffeine | 3 | 2018 | 700 | 0.540 |
Why?
|
| Sex Distribution | 18 | 2017 | 2281 | 0.540 |
Why?
|
| Confidence Intervals | 32 | 2019 | 2927 | 0.530 |
Why?
|
| Logistic Models | 53 | 2022 | 13255 | 0.520 |
Why?
|
| Aged, 80 and over | 103 | 2024 | 58956 | 0.510 |
Why?
|
| Pregnancy | 72 | 2024 | 29862 | 0.510 |
Why?
|
| Body Height | 17 | 2022 | 1570 | 0.510 |
Why?
|
| Stomach Neoplasms | 14 | 2017 | 1459 | 0.510 |
Why?
|
| Melanoma | 20 | 2021 | 5709 | 0.510 |
Why?
|
| Colonic Neoplasms | 17 | 2021 | 2538 | 0.510 |
Why?
|
| Ultraviolet Rays | 8 | 2016 | 1079 | 0.500 |
Why?
|
| Stomach Ulcer | 12 | 2007 | 122 | 0.500 |
Why?
|
| Survival Rate | 37 | 2020 | 12720 | 0.500 |
Why?
|
| Menarche | 15 | 2024 | 532 | 0.490 |
Why?
|
| Environmental Exposure | 16 | 2016 | 4467 | 0.490 |
Why?
|
| Breast | 12 | 2020 | 1966 | 0.490 |
Why?
|
| Prenatal Exposure Delayed Effects | 10 | 2012 | 2509 | 0.490 |
Why?
|
| Research Design | 13 | 2018 | 6178 | 0.480 |
Why?
|
| Weight Gain | 14 | 2020 | 2347 | 0.480 |
Why?
|
| Skin Neoplasms | 20 | 2016 | 5819 | 0.480 |
Why?
|
| Occupations | 10 | 2015 | 515 | 0.470 |
Why?
|
| Exercise | 18 | 2023 | 5884 | 0.450 |
Why?
|
| Body Weight | 19 | 2020 | 4618 | 0.450 |
Why?
|
| Rectal Neoplasms | 13 | 2018 | 1157 | 0.450 |
Why?
|
| Human papillomavirus 16 | 4 | 2019 | 267 | 0.450 |
Why?
|
| Causality | 8 | 2016 | 1243 | 0.440 |
Why?
|
| Nevus | 4 | 2016 | 205 | 0.440 |
Why?
|
| Waist Circumference | 6 | 2017 | 934 | 0.440 |
Why?
|
| Time Factors | 86 | 2020 | 39975 | 0.440 |
Why?
|
| Reproductive History | 8 | 2018 | 211 | 0.430 |
Why?
|
| Herbicides | 5 | 2015 | 105 | 0.430 |
Why?
|
| Breast Implants | 4 | 1998 | 411 | 0.430 |
Why?
|
| Inflammatory Bowel Diseases | 6 | 2023 | 2422 | 0.430 |
Why?
|
| Crohn Disease | 10 | 2023 | 2279 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 15 | 2016 | 4021 | 0.420 |
Why?
|
| Colitis, Ulcerative | 11 | 2022 | 1922 | 0.420 |
Why?
|
| Sex Factors | 51 | 2020 | 10548 | 0.420 |
Why?
|
| Women's Health | 13 | 2017 | 2065 | 0.410 |
Why?
|
| Prognosis | 71 | 2023 | 29620 | 0.410 |
Why?
|
| Reproduction | 8 | 2020 | 645 | 0.410 |
Why?
|
| Diet, Mediterranean | 4 | 2019 | 740 | 0.410 |
Why?
|
| Insecticides | 5 | 2007 | 191 | 0.410 |
Why?
|
| Cause of Death | 14 | 2023 | 3684 | 0.400 |
Why?
|
| Risk Reduction Behavior | 5 | 2017 | 1112 | 0.400 |
Why?
|
| Adolescent | 114 | 2022 | 88313 | 0.400 |
Why?
|
| Fetal Blood | 7 | 2014 | 1347 | 0.400 |
Why?
|
| Motor Activity | 7 | 2015 | 2711 | 0.390 |
Why?
|
| Common Bile Duct Neoplasms | 3 | 2024 | 120 | 0.390 |
Why?
|
| Diethylstilbestrol | 1 | 2012 | 87 | 0.390 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2012 | 52 | 0.390 |
Why?
|
| Diseases in Twins | 5 | 2019 | 447 | 0.390 |
Why?
|
| Leukemia | 6 | 2014 | 1522 | 0.390 |
Why?
|
| Poisson Distribution | 17 | 2012 | 504 | 0.380 |
Why?
|
| Haplotypes | 20 | 2014 | 2775 | 0.380 |
Why?
|
| Clostridium Infections | 1 | 2018 | 558 | 0.380 |
Why?
|
| Epidemiologic Methods | 17 | 2010 | 1336 | 0.380 |
Why?
|
| Prostatic Hyperplasia | 6 | 2007 | 521 | 0.380 |
Why?
|
| Sex Hormone-Binding Globulin | 12 | 2014 | 550 | 0.370 |
Why?
|
| Evidence-Based Medicine | 7 | 2016 | 3687 | 0.370 |
Why?
|
| Genome, Viral | 3 | 2019 | 665 | 0.370 |
Why?
|
| Neoplasm Invasiveness | 15 | 2019 | 3589 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2022 | 9277 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2018 | 1640 | 0.370 |
Why?
|
| Primary Prevention | 3 | 2013 | 1186 | 0.370 |
Why?
|
| Cholecystectomy | 9 | 1996 | 406 | 0.360 |
Why?
|
| Survival Analysis | 33 | 2019 | 10089 | 0.360 |
Why?
|
| Food, Preserved | 2 | 2021 | 13 | 0.360 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 982 | 0.360 |
Why?
|
| Antioxidants | 5 | 2021 | 1669 | 0.360 |
Why?
|
| Regression Analysis | 31 | 2018 | 6343 | 0.360 |
Why?
|
| Toxicology | 1 | 2011 | 102 | 0.360 |
Why?
|
| Finland | 12 | 2019 | 607 | 0.360 |
Why?
|
| Dietary Fats | 10 | 2022 | 1994 | 0.360 |
Why?
|
| Adenocarcinoma | 14 | 2024 | 6339 | 0.350 |
Why?
|
| Fish Products | 3 | 2019 | 30 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 7389 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2023 | 10203 | 0.340 |
Why?
|
| Diet Surveys | 10 | 2009 | 1162 | 0.340 |
Why?
|
| Receptors, Estrogen | 11 | 2020 | 2208 | 0.340 |
Why?
|
| Social Class | 6 | 2014 | 2004 | 0.340 |
Why?
|
| Hydrocarbons, Chlorinated | 4 | 2007 | 120 | 0.340 |
Why?
|
| Alcoholic Beverages | 1 | 2011 | 264 | 0.330 |
Why?
|
| Occupational Exposure | 12 | 2021 | 1813 | 0.330 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2014 | 497 | 0.330 |
Why?
|
| Nobel Prize | 1 | 2009 | 48 | 0.330 |
Why?
|
| Sunbathing | 3 | 2017 | 65 | 0.330 |
Why?
|
| Chronic Disease | 11 | 2018 | 9320 | 0.330 |
Why?
|
| Medical Record Linkage | 13 | 2007 | 285 | 0.320 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2015 | 874 | 0.320 |
Why?
|
| Genome-Wide Association Study | 19 | 2022 | 12688 | 0.320 |
Why?
|
| Aspirin | 6 | 2019 | 3134 | 0.320 |
Why?
|
| Parkinson Disease | 6 | 2022 | 2877 | 0.310 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 5335 | 0.310 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2012 | 262 | 0.310 |
Why?
|
| Epidemiologic Research Design | 3 | 2008 | 368 | 0.310 |
Why?
|
| Overweight | 12 | 2023 | 2413 | 0.310 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 4 | 2015 | 491 | 0.300 |
Why?
|
| Young Adult | 53 | 2024 | 59207 | 0.300 |
Why?
|
| Diabetes Mellitus | 13 | 2016 | 5840 | 0.300 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2021 | 293 | 0.300 |
Why?
|
| Liver Neoplasms | 13 | 2022 | 4320 | 0.300 |
Why?
|
| Hip Fractures | 7 | 2017 | 988 | 0.290 |
Why?
|
| Forecasting | 8 | 2015 | 2928 | 0.290 |
Why?
|
| Africa South of the Sahara | 6 | 2020 | 743 | 0.290 |
Why?
|
| Silicones | 3 | 1998 | 227 | 0.290 |
Why?
|
| Acrylamides | 2 | 2009 | 259 | 0.290 |
Why?
|
| Anthropometry | 5 | 2019 | 1349 | 0.280 |
Why?
|
| Seminoma | 3 | 2013 | 134 | 0.280 |
Why?
|
| Cooking | 1 | 2009 | 315 | 0.280 |
Why?
|
| Iceland | 10 | 2022 | 184 | 0.270 |
Why?
|
| Prevalence | 21 | 2018 | 15717 | 0.270 |
Why?
|
| Tobacco Smoke Pollution | 4 | 2018 | 818 | 0.270 |
Why?
|
| Dietary Proteins | 3 | 2012 | 952 | 0.270 |
Why?
|
| Menopause, Premature | 2 | 2018 | 124 | 0.270 |
Why?
|
| Food Contamination | 3 | 2005 | 191 | 0.270 |
Why?
|
| Infectious Mononucleosis | 3 | 2015 | 133 | 0.270 |
Why?
|
| Precancerous Conditions | 6 | 2023 | 980 | 0.270 |
Why?
|
| Urinary Bladder Neoplasms | 8 | 2021 | 2223 | 0.270 |
Why?
|
| Socioeconomic Factors | 22 | 2019 | 7825 | 0.260 |
Why?
|
| Phytoestrogens | 3 | 2016 | 59 | 0.260 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2006 | 106 | 0.260 |
Why?
|
| Fishes | 2 | 2021 | 603 | 0.260 |
Why?
|
| Journalism, Medical | 2 | 2003 | 73 | 0.250 |
Why?
|
| Early Diagnosis | 2 | 2012 | 1186 | 0.250 |
Why?
|
| Neoplasm Staging | 32 | 2019 | 11106 | 0.250 |
Why?
|
| Genetic Loci | 5 | 2018 | 2631 | 0.250 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 2 | 2015 | 15 | 0.250 |
Why?
|
| Prolactin | 7 | 2014 | 625 | 0.250 |
Why?
|
| Estradiol | 13 | 2008 | 1937 | 0.240 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 2 | 2015 | 25 | 0.240 |
Why?
|
| Food | 7 | 2021 | 772 | 0.240 |
Why?
|
| Germinoma | 2 | 1996 | 132 | 0.240 |
Why?
|
| Uterine Neoplasms | 16 | 2018 | 1420 | 0.240 |
Why?
|
| Hypoglycemic Agents | 3 | 2014 | 3081 | 0.240 |
Why?
|
| Environment | 7 | 2007 | 1122 | 0.240 |
Why?
|
| Caprylates | 2 | 2016 | 115 | 0.240 |
Why?
|
| Conflict of Interest | 2 | 2007 | 554 | 0.230 |
Why?
|
| Environmental Pollutants | 4 | 2015 | 1276 | 0.230 |
Why?
|
| Health Behavior | 7 | 2017 | 2641 | 0.230 |
Why?
|
| Fruit | 6 | 2016 | 1160 | 0.230 |
Why?
|
| Vegetables | 6 | 2016 | 1196 | 0.230 |
Why?
|
| Breast Feeding | 8 | 2018 | 1358 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2018 | 375 | 0.230 |
Why?
|
| Sjogren's Syndrome | 1 | 2006 | 234 | 0.230 |
Why?
|
| Mastectomy | 10 | 2014 | 1822 | 0.230 |
Why?
|
| United States | 43 | 2024 | 72339 | 0.220 |
Why?
|
| Diet, Fat-Restricted | 1 | 2006 | 329 | 0.220 |
Why?
|
| Lung Neoplasms | 14 | 2023 | 13337 | 0.220 |
Why?
|
| Weight Loss | 4 | 2023 | 2683 | 0.220 |
Why?
|
| Estrogen Receptor beta | 4 | 2012 | 168 | 0.220 |
Why?
|
| Public Health | 6 | 2017 | 2666 | 0.220 |
Why?
|
| Stroke | 9 | 2024 | 9756 | 0.220 |
Why?
|
| Adenoids | 1 | 2023 | 35 | 0.220 |
Why?
|
| Receptors, Progesterone | 6 | 2018 | 1129 | 0.220 |
Why?
|
| Pesticides | 4 | 2011 | 295 | 0.220 |
Why?
|
| Estriol | 6 | 2014 | 53 | 0.210 |
Why?
|
| Life Expectancy | 7 | 2018 | 1242 | 0.210 |
Why?
|
| Pigmentation | 1 | 2003 | 144 | 0.210 |
Why?
|
| Mass Media | 2 | 2003 | 303 | 0.210 |
Why?
|
| Mental Disorders | 6 | 2024 | 6841 | 0.210 |
Why?
|
| Breast Neoplasms, Male | 4 | 2001 | 219 | 0.210 |
Why?
|
| Vagotomy | 6 | 2007 | 83 | 0.200 |
Why?
|
| Alkanesulfonic Acids | 2 | 2016 | 201 | 0.200 |
Why?
|
| Clinical Medicine | 1 | 2004 | 145 | 0.200 |
Why?
|
| DDT | 3 | 1997 | 32 | 0.200 |
Why?
|
| Parturition | 3 | 2018 | 445 | 0.200 |
Why?
|
| Biomedical Research | 3 | 2019 | 3429 | 0.200 |
Why?
|
| Urban Population | 5 | 2016 | 2036 | 0.200 |
Why?
|
| Research Personnel | 1 | 2007 | 588 | 0.200 |
Why?
|
| Dimethylnitrosamine | 1 | 2021 | 17 | 0.200 |
Why?
|
| Patient Compliance | 6 | 2019 | 2690 | 0.200 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2022 | 224 | 0.200 |
Why?
|
| Geography | 3 | 2021 | 656 | 0.200 |
Why?
|
| Esophageal Neoplasms | 8 | 2017 | 1649 | 0.200 |
Why?
|
| Skin Pigmentation | 3 | 2010 | 277 | 0.200 |
Why?
|
| Polyps | 2 | 2022 | 200 | 0.200 |
Why?
|
| Telephone | 5 | 2016 | 627 | 0.190 |
Why?
|
| Immunogenetics | 1 | 2001 | 66 | 0.190 |
Why?
|
| Disease Outbreaks | 2 | 2010 | 1749 | 0.190 |
Why?
|
| Family Health | 6 | 2017 | 1257 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 4 | 2010 | 208 | 0.190 |
Why?
|
| Placenta | 5 | 2014 | 1708 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2019 | 2273 | 0.190 |
Why?
|
| Survivors | 3 | 2014 | 2371 | 0.190 |
Why?
|
| Progesterone | 9 | 2014 | 742 | 0.190 |
Why?
|
| Thyroid Neoplasms | 8 | 2024 | 2332 | 0.190 |
Why?
|
| Leukemia, Myeloid | 3 | 2010 | 694 | 0.190 |
Why?
|
| Diuretics | 2 | 1995 | 610 | 0.190 |
Why?
|
| Proctitis | 2 | 1991 | 41 | 0.190 |
Why?
|
| Hematologic Neoplasms | 3 | 2010 | 1896 | 0.190 |
Why?
|
| Occupational Diseases | 5 | 2010 | 1490 | 0.190 |
Why?
|
| Sleep | 7 | 2023 | 4766 | 0.190 |
Why?
|
| Polychlorinated Biphenyls | 2 | 2000 | 235 | 0.190 |
Why?
|
| Metformin | 3 | 2014 | 906 | 0.180 |
Why?
|
| Infant, Newborn | 32 | 2016 | 26212 | 0.180 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 104 | 0.180 |
Why?
|
| Genotype | 23 | 2021 | 13009 | 0.180 |
Why?
|
| Meta-Analysis as Topic | 5 | 2016 | 1377 | 0.180 |
Why?
|
| Chromosomes, Human | 2 | 2014 | 442 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2018 | 1444 | 0.180 |
Why?
|
| Circumcision, Male | 1 | 2002 | 148 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2013 | 452 | 0.180 |
Why?
|
| Alleles | 9 | 2019 | 6922 | 0.180 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2018 | 1469 | 0.180 |
Why?
|
| Child | 44 | 2024 | 80162 | 0.180 |
Why?
|
| Retirement | 2 | 2021 | 198 | 0.180 |
Why?
|
| Residence Characteristics | 6 | 2016 | 2092 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2021 | 3755 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2022 | 2298 | 0.180 |
Why?
|
| Gravidity | 2 | 2018 | 50 | 0.180 |
Why?
|
| Age of Onset | 6 | 2019 | 3304 | 0.170 |
Why?
|
| Physical Exertion | 3 | 2005 | 667 | 0.170 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2022 | 177 | 0.170 |
Why?
|
| Neoplasm Metastasis | 11 | 2018 | 4912 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2014 | 3357 | 0.170 |
Why?
|
| Energy Intake | 10 | 2010 | 2134 | 0.170 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2008 | 410 | 0.170 |
Why?
|
| Birth Rate | 1 | 2001 | 168 | 0.170 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2010 | 198 | 0.170 |
Why?
|
| Accidents | 2 | 2017 | 165 | 0.170 |
Why?
|
| Peer Review, Research | 1 | 2003 | 340 | 0.170 |
Why?
|
| Fluorocarbons | 2 | 2016 | 492 | 0.170 |
Why?
|
| Hemoglobins | 3 | 2010 | 1524 | 0.170 |
Why?
|
| Cheese | 1 | 2019 | 38 | 0.170 |
Why?
|
| Quality Improvement | 1 | 2014 | 3800 | 0.160 |
Why?
|
| Radio Waves | 1 | 2001 | 251 | 0.160 |
Why?
|
| Analgesics | 2 | 2019 | 1070 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 2015 | 418 | 0.160 |
Why?
|
| beta Carotene | 1 | 2021 | 523 | 0.160 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2023 | 384 | 0.160 |
Why?
|
| Mammary Glands, Human | 2 | 2012 | 203 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 1999 | 127 | 0.160 |
Why?
|
| Insufflation | 2 | 2016 | 61 | 0.160 |
Why?
|
| Gestational Age | 12 | 2014 | 3576 | 0.160 |
Why?
|
| Prostate | 7 | 2019 | 1770 | 0.160 |
Why?
|
| Gene Frequency | 11 | 2013 | 3647 | 0.160 |
Why?
|
| Genetic Variation | 16 | 2019 | 6581 | 0.160 |
Why?
|
| Health Surveys | 9 | 2016 | 4059 | 0.160 |
Why?
|
| Formaldehyde | 2 | 2010 | 358 | 0.160 |
Why?
|
| Vulvar Neoplasms | 1 | 2001 | 263 | 0.160 |
Why?
|
| Anus Neoplasms | 6 | 2000 | 329 | 0.160 |
Why?
|
| Milk | 5 | 2019 | 443 | 0.160 |
Why?
|
| Disease Progression | 16 | 2019 | 13502 | 0.160 |
Why?
|
| Sex Characteristics | 6 | 2020 | 2637 | 0.150 |
Why?
|
| Gene Expression Profiling | 8 | 2022 | 9418 | 0.150 |
Why?
|
| Bile Ducts, Extrahepatic | 2 | 2019 | 49 | 0.150 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2016 | 487 | 0.150 |
Why?
|
| Fats, Unsaturated | 1 | 1998 | 21 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 6 | 1999 | 592 | 0.150 |
Why?
|
| Sensitivity and Specificity | 10 | 2013 | 14664 | 0.150 |
Why?
|
| Models, Theoretical | 2 | 2014 | 3576 | 0.150 |
Why?
|
| Bereavement | 2 | 2015 | 308 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2018 | 287 | 0.150 |
Why?
|
| SEER Program | 5 | 2016 | 1450 | 0.150 |
Why?
|
| Treatment Outcome | 16 | 2024 | 64651 | 0.150 |
Why?
|
| Seasons | 4 | 2008 | 1519 | 0.150 |
Why?
|
| Autoimmunity | 1 | 2006 | 1355 | 0.150 |
Why?
|
| Celiac Disease | 1 | 2006 | 825 | 0.150 |
Why?
|
| Hormone Replacement Therapy | 2 | 2000 | 751 | 0.150 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2018 | 97 | 0.150 |
Why?
|
| Gastrectomy | 6 | 2007 | 672 | 0.150 |
Why?
|
| Follicle Stimulating Hormone | 4 | 2004 | 726 | 0.140 |
Why?
|
| Reproducibility of Results | 12 | 2020 | 20093 | 0.140 |
Why?
|
| DNA Repair | 2 | 2007 | 2045 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 3 | 2018 | 582 | 0.140 |
Why?
|
| Ascorbic Acid | 1 | 2021 | 655 | 0.140 |
Why?
|
| Ovarian Diseases | 1 | 2018 | 137 | 0.140 |
Why?
|
| Saliva | 1 | 2022 | 827 | 0.140 |
Why?
|
| Lymphocytosis | 1 | 2018 | 121 | 0.140 |
Why?
|
| Papillomavirus Vaccines | 1 | 2023 | 496 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2007 | 258 | 0.140 |
Why?
|
| Vagotomy, Proximal Gastric | 4 | 1986 | 8 | 0.140 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2007 | 74 | 0.140 |
Why?
|
| Organ Size | 5 | 2013 | 2254 | 0.140 |
Why?
|
| Research | 6 | 2001 | 1977 | 0.140 |
Why?
|
| Pregnancy, Multiple | 2 | 1996 | 215 | 0.140 |
Why?
|
| Analysis of Variance | 12 | 2009 | 6231 | 0.140 |
Why?
|
| Cardiovascular System | 2 | 2024 | 835 | 0.140 |
Why?
|
| Stem Cells | 3 | 2011 | 3522 | 0.140 |
Why?
|
| Self-Examination | 1 | 1996 | 71 | 0.140 |
Why?
|
| Genetic Association Studies | 5 | 2023 | 2734 | 0.140 |
Why?
|
| Review Literature as Topic | 1 | 1999 | 347 | 0.140 |
Why?
|
| Australia | 6 | 2018 | 1250 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1743 | 0.140 |
Why?
|
| Developing Countries | 5 | 2014 | 2885 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2015 | 350 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2691 | 0.130 |
Why?
|
| Vitamin E | 1 | 2021 | 872 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2022 | 552 | 0.130 |
Why?
|
| Sunburn | 1 | 2017 | 156 | 0.130 |
Why?
|
| Siblings | 2 | 2023 | 825 | 0.130 |
Why?
|
| Polymorphism, Genetic | 8 | 2011 | 4287 | 0.130 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 980 | 0.130 |
Why?
|
| Patient Participation | 4 | 2020 | 1444 | 0.130 |
Why?
|
| Climacteric | 6 | 1989 | 57 | 0.130 |
Why?
|
| Health Policy | 3 | 2013 | 2684 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 1 | 1997 | 250 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 1998 | 549 | 0.130 |
Why?
|
| Birth Order | 2 | 2015 | 95 | 0.130 |
Why?
|
| Paraquat | 2 | 2014 | 32 | 0.130 |
Why?
|
| Nevus, Pigmented | 1 | 1998 | 221 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2015 | 1405 | 0.130 |
Why?
|
| Suicide | 4 | 2012 | 1598 | 0.130 |
Why?
|
| Hepatitis B Vaccines | 1 | 2017 | 185 | 0.130 |
Why?
|
| Guideline Adherence | 2 | 2019 | 2220 | 0.130 |
Why?
|
| Fast Foods | 1 | 2018 | 210 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2024 | 6479 | 0.130 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 370 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 4 | 2019 | 1703 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 641 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 9606 | 0.130 |
Why?
|
| Labor, Obstetric | 4 | 1999 | 323 | 0.130 |
Why?
|
| DNA, Neoplasm | 7 | 2009 | 1745 | 0.130 |
Why?
|
| alpha-Fetoproteins | 3 | 2007 | 223 | 0.130 |
Why?
|
| Sarcoma | 3 | 2018 | 1801 | 0.130 |
Why?
|
| Oral Hygiene | 1 | 2016 | 133 | 0.130 |
Why?
|
| Antibodies, Viral | 3 | 2021 | 3155 | 0.130 |
Why?
|
| Dyspepsia | 9 | 1987 | 116 | 0.120 |
Why?
|
| Cimetidine | 9 | 1987 | 76 | 0.120 |
Why?
|
| Leg | 3 | 1996 | 1089 | 0.120 |
Why?
|
| Autoimmune Diseases | 2 | 2019 | 2248 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 415 | 0.120 |
Why?
|
| Viral Proteins | 2 | 2019 | 1803 | 0.120 |
Why?
|
| Statistics as Topic | 7 | 2004 | 2358 | 0.120 |
Why?
|
| Toll-Like Receptors | 4 | 2006 | 589 | 0.120 |
Why?
|
| Neoplasms, Gonadal Tissue | 1 | 1994 | 3 | 0.120 |
Why?
|
| Hepatitis B | 2 | 2017 | 706 | 0.120 |
Why?
|
| Urbanization | 1 | 2015 | 100 | 0.120 |
Why?
|
| Educational Status | 11 | 2019 | 2520 | 0.120 |
Why?
|
| Myocardial Infarction | 5 | 2024 | 11458 | 0.120 |
Why?
|
| Embolectomy | 1 | 1996 | 129 | 0.120 |
Why?
|
| Rural Population | 6 | 2016 | 2285 | 0.120 |
Why?
|
| Carbon Dioxide | 2 | 2016 | 1146 | 0.120 |
Why?
|
| Stress, Psychological | 4 | 2019 | 4477 | 0.120 |
Why?
|
| Connective Tissue Diseases | 1 | 1998 | 285 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2015 | 1081 | 0.120 |
Why?
|
| Acetaminophen | 1 | 2019 | 554 | 0.120 |
Why?
|
| Recreation | 1 | 2015 | 125 | 0.120 |
Why?
|
| Greece | 5 | 2011 | 340 | 0.120 |
Why?
|
| Twins | 3 | 2019 | 340 | 0.120 |
Why?
|
| Occult Blood | 3 | 2023 | 198 | 0.120 |
Why?
|
| Hysterectomy | 4 | 2018 | 857 | 0.120 |
Why?
|
| Nutrition Policy | 2 | 2024 | 471 | 0.120 |
Why?
|
| Uterus | 1 | 2018 | 649 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 2013 | 313 | 0.120 |
Why?
|
| Major Histocompatibility Complex | 2 | 2015 | 927 | 0.120 |
Why?
|
| Wounds and Injuries | 2 | 2017 | 2491 | 0.120 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2002 | 64 | 0.110 |
Why?
|
| Diet Therapy | 1 | 2015 | 150 | 0.110 |
Why?
|
| Meat | 3 | 2005 | 584 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 2 | 2007 | 597 | 0.110 |
Why?
|
| Mastectomy, Segmental | 4 | 2018 | 953 | 0.110 |
Why?
|
| North America | 4 | 2016 | 1276 | 0.110 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1996 | 363 | 0.110 |
Why?
|
| Fixatives | 2 | 2010 | 91 | 0.110 |
Why?
|
| Membrane Glycoproteins | 3 | 2015 | 3702 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2018 | 1355 | 0.110 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2009 | 269 | 0.110 |
Why?
|
| Food Preferences | 1 | 1997 | 398 | 0.110 |
Why?
|
| Immune System Diseases | 1 | 2016 | 257 | 0.110 |
Why?
|
| Iodine | 1 | 1996 | 288 | 0.110 |
Why?
|
| Atrazine | 1 | 2013 | 9 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 178 | 0.110 |
Why?
|
| Seafood | 1 | 2016 | 393 | 0.110 |
Why?
|
| HLA Antigens | 2 | 2019 | 1371 | 0.110 |
Why?
|
| Vitamin D | 3 | 2019 | 3301 | 0.110 |
Why?
|
| Intrauterine Devices | 1 | 2014 | 113 | 0.110 |
Why?
|
| Activities of Daily Living | 3 | 2017 | 2421 | 0.110 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 539 | 0.110 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 2163 | 0.110 |
Why?
|
| Tamoxifen | 1 | 1997 | 965 | 0.110 |
Why?
|
| Cholelithiasis | 2 | 1993 | 407 | 0.110 |
Why?
|
| Abdominal Pain | 2 | 2016 | 1071 | 0.110 |
Why?
|
| Smoking Cessation | 3 | 2018 | 2056 | 0.110 |
Why?
|
| Health Promotion | 2 | 2015 | 2213 | 0.100 |
Why?
|
| Hypertension | 9 | 2016 | 8542 | 0.100 |
Why?
|
| Bread | 1 | 2012 | 23 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 3 | 2016 | 940 | 0.100 |
Why?
|
| Dairy Products | 3 | 2019 | 490 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2016 | 786 | 0.100 |
Why?
|
| Viral Load | 3 | 2012 | 3330 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 374 | 0.100 |
Why?
|
| Measles | 1 | 1994 | 183 | 0.100 |
Why?
|
| Fish Oils | 3 | 2016 | 483 | 0.100 |
Why?
|
| Epidemiologic Factors | 2 | 2008 | 36 | 0.100 |
Why?
|
| Androstenedione | 3 | 1996 | 131 | 0.100 |
Why?
|
| Contraceptives, Oral, Hormonal | 3 | 2004 | 190 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2018 | 8545 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 1069 | 0.100 |
Why?
|
| Communicable Diseases | 2 | 2010 | 875 | 0.100 |
Why?
|
| Cancer Care Facilities | 2 | 2019 | 422 | 0.100 |
Why?
|
| Estrone | 5 | 1996 | 234 | 0.100 |
Why?
|
| Middle East | 2 | 2016 | 231 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2003 | 1463 | 0.100 |
Why?
|
| Disease Susceptibility | 6 | 2019 | 1793 | 0.100 |
Why?
|
| Hormones | 3 | 2010 | 869 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 686 | 0.100 |
Why?
|
| Sleep Deprivation | 2 | 2015 | 843 | 0.100 |
Why?
|
| Feces | 1 | 2018 | 1497 | 0.100 |
Why?
|
| Interleukin-8 | 1 | 2014 | 695 | 0.100 |
Why?
|
| Netherlands | 3 | 2016 | 2221 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 5 | 2000 | 1626 | 0.100 |
Why?
|
| Aging | 5 | 2019 | 8705 | 0.090 |
Why?
|
| Editorial Policies | 1 | 2016 | 458 | 0.090 |
Why?
|
| Reference Values | 6 | 2012 | 4921 | 0.090 |
Why?
|
| Carcinogens, Environmental | 1 | 2011 | 72 | 0.090 |
Why?
|
| Violence | 1 | 2017 | 937 | 0.090 |
Why?
|
| Asia | 4 | 2016 | 619 | 0.090 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 563 | 0.090 |
Why?
|
| Boston | 12 | 2014 | 9330 | 0.090 |
Why?
|
| Asia, Southeastern | 2 | 2012 | 114 | 0.090 |
Why?
|
| Dietary Supplements | 3 | 2018 | 3414 | 0.090 |
Why?
|
| Thinness | 3 | 2019 | 490 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 533 | 0.090 |
Why?
|
| Quality of Life | 7 | 2022 | 13361 | 0.090 |
Why?
|
| Recurrence | 10 | 2018 | 8469 | 0.090 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2018 | 1073 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2010 | 71 | 0.090 |
Why?
|
| Somatotypes | 2 | 2023 | 41 | 0.090 |
Why?
|
| Insulin Resistance | 3 | 2012 | 3963 | 0.090 |
Why?
|
| Self Disclosure | 2 | 2009 | 249 | 0.090 |
Why?
|
| Toxicity Tests | 1 | 2011 | 114 | 0.090 |
Why?
|
| Eating | 3 | 2010 | 1538 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2016 | 560 | 0.090 |
Why?
|
| Receptors, Androgen | 2 | 2007 | 1079 | 0.090 |
Why?
|
| Intracranial Hemorrhages | 1 | 2016 | 822 | 0.090 |
Why?
|
| Animals | 23 | 2021 | 168441 | 0.090 |
Why?
|
| Science | 2 | 2008 | 239 | 0.090 |
Why?
|
| Infant | 19 | 2017 | 36205 | 0.090 |
Why?
|
| Schizophrenia | 6 | 2001 | 6937 | 0.090 |
Why?
|
| Health Services Misuse | 1 | 2012 | 244 | 0.090 |
Why?
|
| Helicobacter Infections | 3 | 2007 | 388 | 0.090 |
Why?
|
| Radioimmunoassay | 5 | 1999 | 865 | 0.090 |
Why?
|
| International Cooperation | 4 | 2018 | 1422 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2016 | 549 | 0.090 |
Why?
|
| Gastritis | 4 | 1985 | 199 | 0.090 |
Why?
|
| Exercise Therapy | 1 | 2017 | 928 | 0.090 |
Why?
|
| Ischemia | 3 | 1996 | 1877 | 0.090 |
Why?
|
| Styrenes | 1 | 2009 | 23 | 0.090 |
Why?
|
| GATA3 Transcription Factor | 1 | 2010 | 152 | 0.090 |
Why?
|
| Cadherins | 2 | 2005 | 904 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2016 | 1890 | 0.090 |
Why?
|
| Hair Color | 2 | 2016 | 131 | 0.090 |
Why?
|
| Walking | 1 | 2017 | 1200 | 0.090 |
Why?
|
| Clinical Trials as Topic | 12 | 2020 | 8000 | 0.080 |
Why?
|
| Somatomedins | 2 | 2013 | 179 | 0.080 |
Why?
|
| Androgens | 2 | 2008 | 1286 | 0.080 |
Why?
|
| Maillard Reaction | 1 | 2009 | 8 | 0.080 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 226 | 0.080 |
Why?
|
| European Union | 3 | 2016 | 157 | 0.080 |
Why?
|
| Human papillomavirus 18 | 1 | 2010 | 125 | 0.080 |
Why?
|
| Inflammation | 5 | 2015 | 10762 | 0.080 |
Why?
|
| Proteome | 1 | 2019 | 1862 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 1551 | 0.080 |
Why?
|
| Hospitals | 2 | 2022 | 3882 | 0.080 |
Why?
|
| Telomere | 1 | 2016 | 941 | 0.080 |
Why?
|
| Predictive Value of Tests | 8 | 2010 | 15262 | 0.080 |
Why?
|
| Dioxins | 1 | 1990 | 91 | 0.080 |
Why?
|
| Brain Ischemia | 2 | 2016 | 3049 | 0.080 |
Why?
|
| Epoxy Compounds | 1 | 2009 | 137 | 0.080 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2022 | 296 | 0.080 |
Why?
|
| Longitudinal Studies | 10 | 2020 | 14599 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2019 | 3446 | 0.080 |
Why?
|
| Reward | 1 | 2016 | 971 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 4549 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2008 | 1606 | 0.080 |
Why?
|
| Tooth Diseases | 1 | 2009 | 74 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2010 | 4014 | 0.080 |
Why?
|
| Somatostatin | 2 | 2009 | 447 | 0.080 |
Why?
|
| Research Support as Topic | 2 | 2007 | 697 | 0.080 |
Why?
|
| Selenoprotein P | 1 | 2008 | 33 | 0.080 |
Why?
|
| Serine Endopeptidases | 3 | 2009 | 1021 | 0.080 |
Why?
|
| Antacids | 6 | 1987 | 94 | 0.080 |
Why?
|
| DNA, Viral | 5 | 2015 | 2201 | 0.080 |
Why?
|
| Interleukin-6 | 3 | 2010 | 3207 | 0.080 |
Why?
|
| Infertility, Female | 1 | 2015 | 760 | 0.080 |
Why?
|
| Central Nervous System Depressants | 1 | 2009 | 164 | 0.080 |
Why?
|
| Multiple Myeloma | 4 | 2015 | 5146 | 0.080 |
Why?
|
| Contraception | 2 | 2014 | 348 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 1994 | 783 | 0.080 |
Why?
|
| Dementia | 1 | 2023 | 2686 | 0.080 |
Why?
|
| Publishing | 1 | 2016 | 833 | 0.080 |
Why?
|
| Lignans | 2 | 2006 | 84 | 0.080 |
Why?
|
| Hip Prosthesis | 1 | 1995 | 921 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 214 | 0.080 |
Why?
|
| Brain Neoplasms | 5 | 2010 | 9031 | 0.080 |
Why?
|
| Child, Preschool | 16 | 2017 | 42254 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2008 | 92 | 0.080 |
Why?
|
| Sexual Maturation | 1 | 1990 | 261 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2017 | 8633 | 0.080 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 26112 | 0.080 |
Why?
|
| Mandatory Reporting | 1 | 2009 | 123 | 0.080 |
Why?
|
| Receptors, Somatostatin | 1 | 2009 | 136 | 0.080 |
Why?
|
| Birth Intervals | 1 | 2008 | 51 | 0.080 |
Why?
|
| Nervous System Diseases | 2 | 1998 | 1666 | 0.080 |
Why?
|
| Waist-Hip Ratio | 3 | 2017 | 518 | 0.080 |
Why?
|
| Data Collection | 6 | 2006 | 3322 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1135 | 0.080 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NAD+) | 1 | 2007 | 1 | 0.080 |
Why?
|
| Triiodothyronine | 3 | 1979 | 493 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 3704 | 0.080 |
Why?
|
| Mouth Neoplasms | 3 | 2007 | 596 | 0.080 |
Why?
|
| Splenectomy | 3 | 1996 | 391 | 0.070 |
Why?
|
| Zinc Compounds | 2 | 2005 | 36 | 0.070 |
Why?
|
| Models, Statistical | 6 | 2014 | 5077 | 0.070 |
Why?
|
| Costs and Cost Analysis | 3 | 2011 | 1668 | 0.070 |
Why?
|
| Diet Records | 1 | 2009 | 427 | 0.070 |
Why?
|
| Information Dissemination | 1 | 2016 | 1126 | 0.070 |
Why?
|
| Glucuronosyltransferase | 1 | 2008 | 132 | 0.070 |
Why?
|
| Chromosomes, Human, Y | 1 | 2008 | 161 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 3 | 2015 | 2892 | 0.070 |
Why?
|
| Liver Cirrhosis | 2 | 2001 | 1934 | 0.070 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2007 | 99 | 0.070 |
Why?
|
| Patient Selection | 4 | 2012 | 4244 | 0.070 |
Why?
|
| Tanzania | 3 | 2016 | 1387 | 0.070 |
Why?
|
| Parents | 3 | 2013 | 3564 | 0.070 |
Why?
|
| Reminder Systems | 2 | 2016 | 388 | 0.070 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2007 | 94 | 0.070 |
Why?
|
| Disease-Free Survival | 5 | 2018 | 6814 | 0.070 |
Why?
|
| Sex Ratio | 1 | 2007 | 108 | 0.070 |
Why?
|
| Insulin | 5 | 2014 | 6602 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1115 | 0.070 |
Why?
|
| Menstrual Cycle | 3 | 1999 | 539 | 0.070 |
Why?
|
| Uganda | 3 | 2016 | 1332 | 0.070 |
Why?
|
| Linear Models | 6 | 2014 | 5869 | 0.070 |
Why?
|
| Amino Acids | 1 | 2013 | 1718 | 0.070 |
Why?
|
| Arctic Regions | 1 | 2006 | 26 | 0.070 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2010 | 545 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 9 | 2015 | 6086 | 0.070 |
Why?
|
| Mouth Diseases | 1 | 2009 | 242 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 992 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2008 | 397 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 4420 | 0.070 |
Why?
|
| Africa, Northern | 1 | 2006 | 86 | 0.070 |
Why?
|
| Heterozygote | 5 | 2018 | 2803 | 0.070 |
Why?
|
| Condylomata Acuminata | 1 | 2006 | 75 | 0.070 |
Why?
|
| Ethanol | 2 | 2009 | 1324 | 0.070 |
Why?
|
| Borrelia burgdorferi | 1 | 2008 | 183 | 0.070 |
Why?
|
| Prostatitis | 1 | 2006 | 102 | 0.070 |
Why?
|
| Introns | 2 | 2006 | 981 | 0.070 |
Why?
|
| Memory | 1 | 1996 | 2187 | 0.070 |
Why?
|
| Thyrotropin | 3 | 1979 | 834 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2015 | 1158 | 0.070 |
Why?
|
| Thyroxine | 3 | 1979 | 668 | 0.070 |
Why?
|
| Tissue Array Analysis | 3 | 2015 | 550 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2011 | 1385 | 0.070 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 594 | 0.070 |
Why?
|
| Death | 1 | 2010 | 676 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 2110 | 0.070 |
Why?
|
| Energy Metabolism | 3 | 2009 | 2881 | 0.060 |
Why?
|
| 4-Butyrolactone | 1 | 2006 | 61 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2009 | 859 | 0.060 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 321 | 0.060 |
Why?
|
| Sexual Behavior | 3 | 2002 | 2179 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 1995 | 2023 | 0.060 |
Why?
|
| National Health Programs | 1 | 2009 | 440 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 297 | 0.060 |
Why?
|
| Psychophysiologic Disorders | 1 | 1987 | 221 | 0.060 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 2 | 1996 | 86 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2018 | 1784 | 0.060 |
Why?
|
| Hyperparathyroidism | 4 | 1988 | 337 | 0.060 |
Why?
|
| Liver | 2 | 2000 | 7532 | 0.060 |
Why?
|
| Nutrition Surveys | 4 | 2016 | 1728 | 0.060 |
Why?
|
| Chlamydia Infections | 1 | 1989 | 365 | 0.060 |
Why?
|
| Retrospective Studies | 20 | 2019 | 80582 | 0.060 |
Why?
|
| Self Report | 5 | 2015 | 3724 | 0.060 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2008 | 237 | 0.060 |
Why?
|
| Testosterone | 4 | 1997 | 2472 | 0.060 |
Why?
|
| Poland | 2 | 2016 | 198 | 0.060 |
Why?
|
| Disease Management | 1 | 2016 | 2507 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 2821 | 0.060 |
Why?
|
| Learning | 1 | 2014 | 1740 | 0.060 |
Why?
|
| Luteinizing Hormone | 2 | 2001 | 820 | 0.060 |
Why?
|
| Uncertainty | 1 | 2010 | 754 | 0.060 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2006 | 262 | 0.060 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 1999 | 116 | 0.060 |
Why?
|
| Specialization | 2 | 2020 | 779 | 0.060 |
Why?
|
| Estrogen Antagonists | 2 | 1995 | 150 | 0.060 |
Why?
|
| Health Status Disparities | 2 | 2018 | 1852 | 0.060 |
Why?
|
| Cardia | 2 | 2001 | 60 | 0.060 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2006 | 170 | 0.060 |
Why?
|
| Suicide, Attempted | 1 | 2013 | 1398 | 0.060 |
Why?
|
| Methods | 3 | 1990 | 1074 | 0.060 |
Why?
|
| Drug Prescriptions | 7 | 2018 | 1669 | 0.060 |
Why?
|
| Racemases and Epimerases | 1 | 2005 | 114 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 316 | 0.060 |
Why?
|
| Food Industry | 1 | 2005 | 67 | 0.060 |
Why?
|
| Food Analysis | 1 | 2005 | 103 | 0.060 |
Why?
|
| Genetic Linkage | 3 | 2008 | 2382 | 0.060 |
Why?
|
| Hepatitis C | 2 | 2008 | 1584 | 0.060 |
Why?
|
| Propantheline | 3 | 1982 | 6 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2455 | 0.060 |
Why?
|
| Guanidines | 2 | 1982 | 193 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2006 | 412 | 0.060 |
Why?
|
| Cost of Illness | 2 | 2010 | 1936 | 0.060 |
Why?
|
| Program Evaluation | 2 | 2009 | 2494 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2010 | 1474 | 0.060 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2014 | 731 | 0.060 |
Why?
|
| Iron, Dietary | 1 | 2005 | 148 | 0.060 |
Why?
|
| Eye Color | 1 | 2003 | 36 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 10766 | 0.060 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2007 | 345 | 0.060 |
Why?
|
| Fertility | 2 | 1999 | 771 | 0.060 |
Why?
|
| Population | 2 | 1994 | 141 | 0.060 |
Why?
|
| Phyllodes Tumor | 1 | 1984 | 53 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 1 | 2004 | 420 | 0.060 |
Why?
|
| Gallbladder Diseases | 2 | 1984 | 141 | 0.060 |
Why?
|
| Linkage Disequilibrium | 4 | 2013 | 2005 | 0.060 |
Why?
|
| Kidney Calculi | 3 | 1997 | 463 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2004 | 2242 | 0.060 |
Why?
|
| Carotenoids | 1 | 2006 | 621 | 0.060 |
Why?
|
| Likelihood Functions | 3 | 2014 | 992 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1771 | 0.050 |
Why?
|
| Schizotypal Personality Disorder | 3 | 1996 | 290 | 0.050 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2003 | 23 | 0.050 |
Why?
|
| Area Under Curve | 3 | 2016 | 1638 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 1062 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 12143 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2011 | 1292 | 0.050 |
Why?
|
| Nigeria | 2 | 2016 | 770 | 0.050 |
Why?
|
| Probability | 3 | 1999 | 2478 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1993 | 3769 | 0.050 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2016 | 1390 | 0.050 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2006 | 351 | 0.050 |
Why?
|
| Endometrial Hyperplasia | 2 | 1999 | 97 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 1784 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2871 | 0.050 |
Why?
|
| Endoribonucleases | 1 | 2004 | 228 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1722 | 0.050 |
Why?
|
| Membrane Proteins | 3 | 2016 | 7856 | 0.050 |
Why?
|
| Palatine Tonsil | 1 | 2023 | 193 | 0.050 |
Why?
|
| Health Status | 2 | 2024 | 4075 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2006 | 759 | 0.050 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2004 | 160 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2008 | 1520 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2009 | 1440 | 0.050 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2006 | 389 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2002 | 58 | 0.050 |
Why?
|
| Beverages | 1 | 2007 | 821 | 0.050 |
Why?
|
| Biopsy | 4 | 2019 | 6766 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2008 | 3810 | 0.050 |
Why?
|
| Comorbidity | 5 | 2015 | 10498 | 0.050 |
Why?
|
| Pregnancy Complications | 2 | 2012 | 2947 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2004 | 559 | 0.050 |
Why?
|
| Lyme Disease | 1 | 2008 | 631 | 0.050 |
Why?
|
| Helicobacter pylori | 3 | 2007 | 377 | 0.050 |
Why?
|
| Genital Diseases, Male | 1 | 2002 | 83 | 0.050 |
Why?
|
| Hepatitis, Chronic | 1 | 2001 | 52 | 0.050 |
Why?
|
| Paternal Age | 2 | 2015 | 87 | 0.050 |
Why?
|
| Titanium | 1 | 2004 | 484 | 0.050 |
Why?
|
| Coronary Disease | 3 | 2019 | 5919 | 0.050 |
Why?
|
| Drug Administration Schedule | 4 | 2018 | 4852 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2004 | 431 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 4 | 2006 | 5789 | 0.050 |
Why?
|
| Genetic Markers | 3 | 2015 | 2613 | 0.050 |
Why?
|
| Thyroid Gland | 2 | 1979 | 1168 | 0.050 |
Why?
|
| Models, Biological | 5 | 2012 | 9469 | 0.050 |
Why?
|
| Autoantigens | 1 | 2006 | 892 | 0.050 |
Why?
|
| Social Environment | 3 | 2015 | 1020 | 0.050 |
Why?
|
| Comprehension | 1 | 2007 | 621 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2001 | 141 | 0.050 |
Why?
|
| Disclosure | 1 | 2007 | 748 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2008 | 2208 | 0.050 |
Why?
|
| Schizophrenic Psychology | 3 | 1999 | 1647 | 0.050 |
Why?
|
| Family | 3 | 2018 | 3197 | 0.050 |
Why?
|
| Mutation | 2 | 2024 | 30045 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2004 | 882 | 0.050 |
Why?
|
| Wilms Tumor | 3 | 1992 | 379 | 0.050 |
Why?
|
| Mental Health | 1 | 2015 | 3249 | 0.040 |
Why?
|
| Postoperative Period | 5 | 1999 | 1815 | 0.040 |
Why?
|
| South Africa | 2 | 2016 | 1841 | 0.040 |
Why?
|
| Maryland | 1 | 2001 | 277 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 2 | 2009 | 2656 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2008 | 2667 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 1997 | 241 | 0.040 |
Why?
|
| Spouses | 1 | 2023 | 283 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 4414 | 0.040 |
Why?
|
| Pregnancy, High-Risk | 2 | 1998 | 122 | 0.040 |
Why?
|
| Prothrombin Time | 1 | 2000 | 117 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2008 | 2769 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2015 | 8487 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 2022 | 290 | 0.040 |
Why?
|
| Growth | 1 | 2022 | 365 | 0.040 |
Why?
|
| Infant, Premature | 2 | 2000 | 2104 | 0.040 |
Why?
|
| Jaundice, Neonatal | 3 | 1995 | 71 | 0.040 |
Why?
|
| Porphyrias, Hepatic | 1 | 1999 | 6 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2002 | 326 | 0.040 |
Why?
|
| Androgen Antagonists | 2 | 2014 | 1410 | 0.040 |
Why?
|
| Beta-Globulins | 1 | 1979 | 27 | 0.040 |
Why?
|
| Phenols | 2 | 2008 | 517 | 0.040 |
Why?
|
| Skin Diseases, Infectious | 1 | 2019 | 76 | 0.040 |
Why?
|
| Yogurt | 1 | 2019 | 71 | 0.040 |
Why?
|
| Pre-Eclampsia | 4 | 2003 | 1231 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 3396 | 0.040 |
Why?
|
| Phosphorus, Dietary | 1 | 1998 | 20 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2009 | 2856 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2012 | 293 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2001 | 469 | 0.040 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 8529 | 0.040 |
Why?
|
| Fund Raising | 1 | 1999 | 49 | 0.040 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 1998 | 40 | 0.040 |
Why?
|
| Estrogens, Conjugated (USP) | 4 | 1993 | 276 | 0.040 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1999 | 165 | 0.040 |
Why?
|
| Hemangioma | 1 | 2004 | 727 | 0.040 |
Why?
|
| Women, Working | 1 | 1999 | 86 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 161 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 634 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 709 | 0.040 |
Why?
|
| Hospitalization | 7 | 2016 | 10718 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2019 | 196 | 0.040 |
Why?
|
| Sigmoid Neoplasms | 1 | 2018 | 54 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 2024 | 888 | 0.040 |
Why?
|
| Serum Albumin | 2 | 2000 | 675 | 0.040 |
Why?
|
| Hematologic Diseases | 2 | 1996 | 496 | 0.040 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2018 | 73 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 1979 | 329 | 0.040 |
Why?
|
| Palliative Care | 4 | 2020 | 3600 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2000 | 347 | 0.040 |
Why?
|
| Random Allocation | 9 | 1989 | 2394 | 0.040 |
Why?
|
| Adipokines | 2 | 2011 | 310 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 2003 | 638 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Health Records, Personal | 1 | 2019 | 127 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1978 | 158 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2006 | 2611 | 0.040 |
Why?
|
| Correspondence as Topic | 1 | 1998 | 35 | 0.040 |
Why?
|
| Ditiocarb | 1 | 1997 | 6 | 0.040 |
Why?
|
| Creosote | 1 | 1997 | 3 | 0.040 |
Why?
|
| Chlordan | 1 | 1997 | 5 | 0.040 |
Why?
|
| Heterosexuality | 1 | 2000 | 309 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2008 | 748 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 266 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2011 | 3243 | 0.040 |
Why?
|
| Pacific Islands | 1 | 1997 | 52 | 0.040 |
Why?
|
| Urban Health | 2 | 2016 | 533 | 0.040 |
Why?
|
| Commerce | 1 | 2003 | 606 | 0.040 |
Why?
|
| Peptic Ulcer | 4 | 1987 | 217 | 0.040 |
Why?
|
| Fetus | 2 | 2003 | 1864 | 0.040 |
Why?
|
| Americas | 1 | 1997 | 111 | 0.040 |
Why?
|
| Lymphatic Metastasis | 6 | 1993 | 2914 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2002 | 796 | 0.040 |
Why?
|
| Recombination, Genetic | 2 | 2013 | 1525 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 537 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2003 | 3441 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 82 | 0.040 |
Why?
|
| Japan | 2 | 2016 | 1371 | 0.040 |
Why?
|
| Surgery, Plastic | 2 | 1998 | 643 | 0.040 |
Why?
|
| Arsenicals | 1 | 1997 | 118 | 0.030 |
Why?
|
| Europe, Eastern | 1 | 2016 | 72 | 0.030 |
Why?
|
| Protective Devices | 1 | 1997 | 72 | 0.030 |
Why?
|
| Melanosis | 1 | 1998 | 93 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2005 | 1876 | 0.030 |
Why?
|
| Pregnancy Outcome | 3 | 2020 | 2920 | 0.030 |
Why?
|
| Nutrition Assessment | 2 | 2004 | 728 | 0.030 |
Why?
|
| Sunscreening Agents | 1 | 2017 | 139 | 0.030 |
Why?
|
| Thyroid Diseases | 2 | 1991 | 386 | 0.030 |
Why?
|
| Adiponectin | 2 | 2014 | 1113 | 0.030 |
Why?
|
| Ureteral Calculi | 1 | 1997 | 114 | 0.030 |
Why?
|
| Mutagens | 1 | 1997 | 179 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2018 | 341 | 0.030 |
Why?
|
| Nurses | 2 | 2016 | 2478 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1998 | 712 | 0.030 |
Why?
|
| Levonorgestrel | 2 | 1993 | 74 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 1996 | 74 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2004 | 1189 | 0.030 |
Why?
|
| Drug Industry | 1 | 2003 | 788 | 0.030 |
Why?
|
| Dihydrotestosterone | 1 | 1997 | 195 | 0.030 |
Why?
|
| Social Support | 1 | 2006 | 2172 | 0.030 |
Why?
|
| Swimming | 1 | 2017 | 208 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2017 | 246 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2001 | 3204 | 0.030 |
Why?
|
| Personality Disorders | 3 | 1996 | 722 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 522 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 713 | 0.030 |
Why?
|
| Toll-Like Receptor 10 | 2 | 2006 | 12 | 0.030 |
Why?
|
| Hospital Departments | 2 | 1986 | 134 | 0.030 |
Why?
|
| Toll-Like Receptor 6 | 2 | 2006 | 29 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 1979 | 404 | 0.030 |
Why?
|
| Lithotripsy | 1 | 1997 | 140 | 0.030 |
Why?
|
| Jaundice | 1 | 1996 | 94 | 0.030 |
Why?
|
| Biometry | 1 | 1999 | 563 | 0.030 |
Why?
|
| Calcium, Dietary | 1 | 1998 | 529 | 0.030 |
Why?
|
| Toll-Like Receptor 1 | 2 | 2006 | 48 | 0.030 |
Why?
|
| Life Tables | 1 | 1996 | 365 | 0.030 |
Why?
|
| Germany | 2 | 1995 | 875 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2016 | 175 | 0.030 |
Why?
|
| Prehypertension | 1 | 2015 | 63 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2004 | 1958 | 0.030 |
Why?
|
| ROC Curve | 2 | 2016 | 3580 | 0.030 |
Why?
|
| Individuality | 1 | 2017 | 300 | 0.030 |
Why?
|
| Baltic States | 1 | 1994 | 3 | 0.030 |
Why?
|
| Triazines | 1 | 1997 | 311 | 0.030 |
Why?
|
| Adipose Tissue | 2 | 1995 | 3312 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 410 | 0.030 |
Why?
|
| Surgery Department, Hospital | 2 | 1986 | 176 | 0.030 |
Why?
|
| Awareness | 1 | 1999 | 647 | 0.030 |
Why?
|
| Pylorus | 4 | 1986 | 86 | 0.030 |
Why?
|
| Africa | 1 | 1997 | 710 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1999 | 756 | 0.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 217 | 0.030 |
Why?
|
| Pancreatic Polypeptide | 2 | 1986 | 34 | 0.030 |
Why?
|
| Ambulatory Care | 3 | 1985 | 2775 | 0.030 |
Why?
|
| Rural Health | 1 | 2016 | 297 | 0.030 |
Why?
|
| Food, Fortified | 1 | 1996 | 189 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 732 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 1529 | 0.030 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 224 | 0.030 |
Why?
|
| Colon | 1 | 2022 | 1792 | 0.030 |
Why?
|
| Gastrins | 2 | 1986 | 74 | 0.030 |
Why?
|
| Internet | 1 | 2007 | 3092 | 0.030 |
Why?
|
| Cohort Effect | 2 | 1991 | 39 | 0.030 |
Why?
|
| Serpins | 1 | 2016 | 247 | 0.030 |
Why?
|
| Tooth Loss | 1 | 2016 | 199 | 0.030 |
Why?
|
| Phylogeny | 1 | 2022 | 2811 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2000 | 719 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1982 | 1403 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 2 | 2001 | 514 | 0.030 |
Why?
|
| Postoperative Complications | 11 | 1994 | 15650 | 0.030 |
Why?
|
| Sulfasalazine | 1 | 1994 | 84 | 0.030 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 1994 | 62 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 1994 | 283 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 1995 | 147 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2022 | 1808 | 0.030 |
Why?
|
| Selection Bias | 2 | 2007 | 359 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2017 | 642 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2000 | 5492 | 0.030 |
Why?
|
| Workplace | 1 | 2020 | 863 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2023 | 2416 | 0.030 |
Why?
|
| Program Development | 2 | 2012 | 1298 | 0.030 |
Why?
|
| Homozygote | 2 | 2010 | 1796 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2018 | 4016 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1994 | 107 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 1997 | 314 | 0.030 |
Why?
|
| Vitamin A | 1 | 1996 | 613 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 4638 | 0.030 |
Why?
|
| Paranoid Personality Disorder | 1 | 1993 | 7 | 0.030 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2016 | 276 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2016 | 469 | 0.030 |
Why?
|
| Actuarial Analysis | 6 | 1989 | 374 | 0.030 |
Why?
|
| Schizoid Personality Disorder | 1 | 1993 | 14 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2003 | 1157 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 803 | 0.030 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2013 | 71 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2017 | 773 | 0.030 |
Why?
|
| Industry | 2 | 2010 | 364 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 636 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 2065 | 0.030 |
Why?
|
| Occupational Health | 1 | 1999 | 806 | 0.030 |
Why?
|
| Morbidity | 3 | 1996 | 1750 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 2000 | 817 | 0.030 |
Why?
|
| Interviews as Topic | 4 | 2000 | 2696 | 0.030 |
Why?
|
| Phenotype | 4 | 2008 | 16606 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2011 | 11526 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 2687 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 675 | 0.030 |
Why?
|
| Eye Movements | 1 | 1996 | 511 | 0.030 |
Why?
|
| Computational Biology | 2 | 2015 | 3517 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4575 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2012 | 197 | 0.030 |
Why?
|
| Inpatients | 2 | 1999 | 2548 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1996 | 323 | 0.030 |
Why?
|
| Pancreatitis | 2 | 2002 | 1096 | 0.030 |
Why?
|
| Dental Caries | 1 | 2016 | 425 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2016 | 517 | 0.020 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 1994 | 295 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 1994 | 307 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2007 | 463 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 123 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1997 | 1230 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 478 | 0.020 |
Why?
|
| Medical Records | 2 | 2003 | 1407 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 11073 | 0.020 |
Why?
|
| Immunoglobulin E | 2 | 2009 | 1495 | 0.020 |
Why?
|
| Aromatase | 1 | 2012 | 147 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1997 | 662 | 0.020 |
Why?
|
| Aminopeptidases | 1 | 2012 | 95 | 0.020 |
Why?
|
| Integrin alpha6 | 1 | 2011 | 30 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 15838 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 719 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 2510 | 0.020 |
Why?
|
| Milk, Human | 1 | 1996 | 484 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 162 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 1199 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2019 | 1392 | 0.020 |
Why?
|
| Embalming | 1 | 2010 | 13 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2005 | 579 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2011 | 188 | 0.020 |
Why?
|
| Social Adjustment | 2 | 1993 | 632 | 0.020 |
Why?
|
| Cryptorchidism | 1 | 1991 | 151 | 0.020 |
Why?
|
| Menstruation | 2 | 1986 | 307 | 0.020 |
Why?
|
| Phenoxyacetates | 1 | 1990 | 1 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 1135 | 0.020 |
Why?
|
| Oral Health | 1 | 2016 | 491 | 0.020 |
Why?
|
| Drug Therapy, Combination | 5 | 2002 | 6309 | 0.020 |
Why?
|
| Functional Laterality | 2 | 1994 | 2256 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 1994 | 444 | 0.020 |
Why?
|
| Chlorophenols | 1 | 1990 | 16 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 785 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 795 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1999 | 2025 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2011 | 211 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2024 | 6238 | 0.020 |
Why?
|
| Abortion, Legal | 1 | 1991 | 114 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 2 | 1997 | 1474 | 0.020 |
Why?
|
| Heart Failure | 1 | 2014 | 11674 | 0.020 |
Why?
|
| Graves Disease | 1 | 1991 | 238 | 0.020 |
Why?
|
| Acute Disease | 3 | 1996 | 7238 | 0.020 |
Why?
|
| Asthma | 2 | 2016 | 6211 | 0.020 |
Why?
|
| Cluster Analysis | 2 | 2014 | 2706 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 413 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 277 | 0.020 |
Why?
|
| Water Supply | 1 | 2011 | 204 | 0.020 |
Why?
|
| Nausea | 2 | 2003 | 679 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2013 | 815 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3514 | 0.020 |
Why?
|
| Axilla | 3 | 1994 | 624 | 0.020 |
Why?
|
| Hypercalcemia | 3 | 1987 | 423 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 897 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2004 | 3979 | 0.020 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1989 | 62 | 0.020 |
Why?
|
| Vomiting | 2 | 2003 | 652 | 0.020 |
Why?
|
| Iran | 1 | 2012 | 738 | 0.020 |
Why?
|
| Terminology as Topic | 2 | 1988 | 1535 | 0.020 |
Why?
|
| Cytokines | 1 | 2004 | 7392 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 3 | 2004 | 4741 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 1386 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2018 | 4278 | 0.020 |
Why?
|
| Disinfectants | 1 | 2010 | 130 | 0.020 |
Why?
|
| Body Composition | 2 | 2017 | 2422 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2010 | 419 | 0.020 |
Why?
|
| Family Characteristics | 1 | 1994 | 1003 | 0.020 |
Why?
|
| Hernia, Inguinal | 1 | 1991 | 220 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 3418 | 0.020 |
Why?
|
| Benzimidazoles | 2 | 1984 | 858 | 0.020 |
Why?
|
| Lymph Nodes | 3 | 2012 | 3466 | 0.020 |
Why?
|
| Blood Donors | 1 | 2010 | 345 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2013 | 939 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 599 | 0.020 |
Why?
|
| Arm | 1 | 1991 | 590 | 0.020 |
Why?
|
| Ticks | 1 | 2008 | 70 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 2009 | 321 | 0.020 |
Why?
|
| Mathematics | 1 | 1989 | 707 | 0.020 |
Why?
|
| Telomerase | 1 | 2013 | 745 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 1169 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2013 | 567 | 0.020 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2008 | 79 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 1993 | 532 | 0.020 |
Why?
|
| Genome, Human | 2 | 2011 | 4425 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 1998 | 2985 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2008 | 23441 | 0.020 |
Why?
|
| Absenteeism | 2 | 1986 | 247 | 0.020 |
Why?
|
| Health | 1 | 2010 | 398 | 0.020 |
Why?
|
| Propionates | 1 | 2008 | 183 | 0.020 |
Why?
|
| Medicine | 1 | 1996 | 941 | 0.020 |
Why?
|
| Base Sequence | 1 | 2018 | 12450 | 0.020 |
Why?
|
| Bites and Stings | 1 | 2008 | 93 | 0.020 |
Why?
|
| Salmon | 1 | 2007 | 34 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2010 | 649 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 2423 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 727 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 2826 | 0.020 |
Why?
|
| Down Syndrome | 1 | 1995 | 901 | 0.020 |
Why?
|
| Drug Utilization | 4 | 2005 | 1188 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3639 | 0.020 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2007 | 59 | 0.020 |
Why?
|
| Metals | 1 | 2011 | 718 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1978 | 1923 | 0.020 |
Why?
|
| Agriculture | 1 | 2008 | 191 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2007 | 190 | 0.020 |
Why?
|
| Epidemics | 1 | 2012 | 511 | 0.020 |
Why?
|
| Employment | 2 | 2006 | 1118 | 0.020 |
Why?
|
| Poverty | 1 | 1998 | 2697 | 0.020 |
Why?
|
| Lectins | 1 | 2008 | 491 | 0.020 |
Why?
|
| Spain | 1 | 2008 | 489 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2007 | 257 | 0.020 |
Why?
|
| Life Change Events | 1 | 1991 | 952 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 1996 | 6019 | 0.020 |
Why?
|
| Carbonated Beverages | 1 | 2007 | 209 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2015 | 2488 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Motivation | 1 | 2016 | 2006 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 1991 | 452 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 2116 | 0.020 |
Why?
|
| Marriage | 2 | 1978 | 351 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2008 | 352 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 1999 | 3068 | 0.020 |
Why?
|
| Selenium | 1 | 2008 | 417 | 0.020 |
Why?
|
| Vitamins | 1 | 1994 | 1634 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2007 | 313 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2012 | 2898 | 0.020 |
Why?
|
| Sepsis | 1 | 2019 | 2585 | 0.020 |
Why?
|
| Triglycerides | 1 | 1993 | 2460 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2007 | 221 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 855 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 1721 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 2898 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 16979 | 0.020 |
Why?
|
| Reference Standards | 1 | 2009 | 1004 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2005 | 90 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2008 | 729 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 1990 | 533 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 1970 | 0.020 |
Why?
|
| Military Personnel | 1 | 2014 | 1246 | 0.020 |
Why?
|
| Methoxyflurane | 2 | 1996 | 5 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2811 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 1600 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2851 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 1647 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2008 | 1992 | 0.010 |
Why?
|
| Radiography | 1 | 1996 | 6966 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1706 | 0.010 |
Why?
|
| Breast Diseases | 1 | 1988 | 442 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 4764 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2006 | 783 | 0.010 |
Why?
|
| Founder Effect | 1 | 2005 | 186 | 0.010 |
Why?
|
| Job Description | 1 | 2004 | 59 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2007 | 412 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 540 | 0.010 |
Why?
|
| Eclampsia | 2 | 1996 | 56 | 0.010 |
Why?
|
| Cholesterol | 1 | 1993 | 2902 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 1529 | 0.010 |
Why?
|
| Parathyroid Glands | 1 | 1986 | 518 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 1843 | 0.010 |
Why?
|
| Singapore | 1 | 2005 | 291 | 0.010 |
Why?
|
| Health Care Reform | 1 | 2013 | 1246 | 0.010 |
Why?
|
| Gene Fusion | 1 | 2007 | 356 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2005 | 299 | 0.010 |
Why?
|
| Psychotherapy, Group | 1 | 1987 | 412 | 0.010 |
Why?
|
| Anti-Ulcer Agents | 1 | 1984 | 112 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 4510 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2529 | 0.010 |
Why?
|
| Preconception Care | 1 | 2004 | 141 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 1994 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2007 | 1218 | 0.010 |
Why?
|
| Referral and Consultation | 3 | 1985 | 3600 | 0.010 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2003 | 79 | 0.010 |
Why?
|
| Nitriles | 1 | 2008 | 971 | 0.010 |
Why?
|
| Actins | 2 | 2000 | 2050 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10441 | 0.010 |
Why?
|
| Multigene Family | 1 | 2006 | 1077 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2018 | 3812 | 0.010 |
Why?
|
| Particulate Matter | 1 | 2014 | 2595 | 0.010 |
Why?
|
| Physical Fitness | 1 | 2006 | 739 | 0.010 |
Why?
|
| Osteoporosis | 1 | 1992 | 1605 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2008 | 1469 | 0.010 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 1458 | 0.010 |
Why?
|
| Fetal Development | 1 | 2007 | 769 | 0.010 |
Why?
|
| Patient Admission | 1 | 1989 | 1367 | 0.010 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 519 | 0.010 |
Why?
|
| Dust | 1 | 2004 | 487 | 0.010 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2001 | 113 | 0.010 |
Why?
|
| Drug Combinations | 4 | 1992 | 2048 | 0.010 |
Why?
|
| DNA | 2 | 2005 | 7219 | 0.010 |
Why?
|
| Homeostasis | 1 | 2012 | 3321 | 0.010 |
Why?
|
| Clonorchiasis | 1 | 2000 | 5 | 0.010 |
Why?
|
| Mental Recall | 1 | 1987 | 1214 | 0.010 |
Why?
|
| Aminophylline | 1 | 2000 | 41 | 0.010 |
Why?
|
| Anxiety | 3 | 2010 | 4572 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 1982 | 258 | 0.010 |
Why?
|
| Eggs | 1 | 2002 | 182 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2008 | 5036 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 3613 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5868 | 0.010 |
Why?
|
| Receptors, Estradiol | 1 | 1980 | 18 | 0.010 |
Why?
|
| Veterans | 1 | 2014 | 2647 | 0.010 |
Why?
|
| Air Pollution | 1 | 2014 | 2348 | 0.010 |
Why?
|
| Transfection | 1 | 2008 | 5775 | 0.010 |
Why?
|
| Spleen | 2 | 1996 | 2295 | 0.010 |
Why?
|
| Schistosomiasis | 1 | 2000 | 65 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2003 | 583 | 0.010 |
Why?
|
| Algorithms | 1 | 2021 | 14026 | 0.010 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 12970 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 5665 | 0.010 |
Why?
|
| Air Pollutants | 1 | 2014 | 2881 | 0.010 |
Why?
|
| Mothers | 1 | 2010 | 2192 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 2393 | 0.010 |
Why?
|
| Patients | 1 | 1986 | 906 | 0.010 |
Why?
|
| Hepatitis C Antibodies | 1 | 2000 | 146 | 0.010 |
Why?
|
| Healthy Worker Effect | 1 | 1999 | 29 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2006 | 1173 | 0.010 |
Why?
|
| Tongue Neoplasms | 1 | 2001 | 183 | 0.010 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 1999 | 11 | 0.010 |
Why?
|
| Porphyria, Acute Intermittent | 1 | 1999 | 15 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2008 | 2846 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 2004 | 869 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 1992 | 2046 | 0.010 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 1999 | 109 | 0.010 |
Why?
|
| Cholinergic Antagonists | 1 | 2000 | 168 | 0.010 |
Why?
|
| Counseling | 1 | 1987 | 1546 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 1699 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 2000 | 329 | 0.010 |
Why?
|
| Fissure in Ano | 1 | 1998 | 14 | 0.010 |
Why?
|
| Administration, Intravaginal | 1 | 1999 | 150 | 0.010 |
Why?
|
| Expert Testimony | 1 | 2001 | 363 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 2004 | 891 | 0.010 |
Why?
|
| Health Services Research | 1 | 1986 | 1812 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2000 | 345 | 0.010 |
Why?
|
| Gene Expression | 1 | 2011 | 7584 | 0.010 |
Why?
|
| Resins, Plant | 1 | 1978 | 20 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 3823 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2000 | 302 | 0.010 |
Why?
|
| Anus Diseases | 1 | 1998 | 55 | 0.010 |
Why?
|
| Intelligence | 1 | 2004 | 924 | 0.010 |
Why?
|
| Xeromammography | 1 | 1978 | 21 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 1986 | 1403 | 0.010 |
Why?
|
| Rectal Fistula | 1 | 1998 | 75 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2002 | 578 | 0.010 |
Why?
|
| Patient Discharge | 1 | 1991 | 3441 | 0.010 |
Why?
|
| Cell Survival | 1 | 2008 | 5790 | 0.010 |
Why?
|
| Community Health Services | 1 | 1983 | 656 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 2471 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 1979 | 289 | 0.010 |
Why?
|
| Palpation | 1 | 1978 | 166 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2008 | 2007 | 0.010 |
Why?
|
| Nutrition Disorders | 1 | 1998 | 205 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1979 | 337 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 4110 | 0.010 |
Why?
|
| Imidazoles | 1 | 1983 | 1180 | 0.010 |
Why?
|
| Fasting | 2 | 2000 | 1602 | 0.010 |
Why?
|
| Maternal Exposure | 1 | 2004 | 1063 | 0.010 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1998 | 340 | 0.010 |
Why?
|
| Delivery, Obstetric | 2 | 1996 | 940 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1987 | 3550 | 0.010 |
Why?
|
| Sexuality | 1 | 1998 | 180 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1984 | 1272 | 0.010 |
Why?
|
| Brain | 1 | 2004 | 27107 | 0.010 |
Why?
|
| Ureteral Neoplasms | 1 | 1997 | 106 | 0.010 |
Why?
|
| Colonic Diseases, Functional | 2 | 1987 | 39 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2000 | 570 | 0.010 |
Why?
|
| Endoscopy | 2 | 1987 | 1851 | 0.010 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1996 | 58 | 0.010 |
Why?
|
| Calcium | 2 | 1987 | 5727 | 0.010 |
Why?
|
| Pursuit, Smooth | 1 | 1996 | 38 | 0.010 |
Why?
|
| Apgar Score | 1 | 1996 | 126 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2000 | 973 | 0.010 |
Why?
|
| Cell Count | 1 | 1980 | 1835 | 0.010 |
Why?
|
| Splenic Diseases | 1 | 1996 | 90 | 0.010 |
Why?
|
| Pelvic Neoplasms | 1 | 1997 | 247 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2005 | 1906 | 0.010 |
Why?
|
| Asphyxia Neonatorum | 1 | 1996 | 111 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2004 | 2571 | 0.010 |
Why?
|
| Emigration and Immigration | 1 | 1998 | 396 | 0.010 |
Why?
|
| Abscess | 1 | 1998 | 606 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 1998 | 999 | 0.010 |
Why?
|
| Digestive System Diseases | 1 | 1996 | 151 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2001 | 1192 | 0.010 |
Why?
|
| Parathyroid Neoplasms | 2 | 1987 | 242 | 0.010 |
Why?
|
| Obstetric Labor, Premature | 1 | 1996 | 272 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 3538 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1980 | 1626 | 0.010 |
Why?
|
| Saccades | 1 | 1996 | 234 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1996 | 457 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 2000 | 1132 | 0.010 |
Why?
|
| Narcotics | 1 | 1996 | 336 | 0.010 |
Why?
|
| Pain | 3 | 1986 | 5071 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2000 | 1037 | 0.010 |
Why?
|
| Parasympatholytics | 2 | 1984 | 89 | 0.010 |
Why?
|
| Bacterial Infections | 2 | 1996 | 1393 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1980 | 1803 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1982 | 1815 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 2319 | 0.010 |
Why?
|
| Omeprazole | 2 | 1984 | 105 | 0.010 |
Why?
|
| Melatonin | 1 | 1978 | 669 | 0.010 |
Why?
|
| Ependymoma | 1 | 1996 | 320 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2007 | 4391 | 0.010 |
Why?
|
| Wales | 1 | 1992 | 87 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 1980 | 1165 | 0.010 |
Why?
|
| Developed Countries | 1 | 1996 | 449 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1995 | 614 | 0.010 |
Why?
|
| Tobacco Use Disorder | 1 | 1998 | 703 | 0.010 |
Why?
|
| Personality Development | 1 | 1993 | 244 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1996 | 1571 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 36423 | 0.010 |
Why?
|
| Divorce | 1 | 1991 | 75 | 0.010 |
Why?
|
| Astrocytoma | 1 | 1996 | 775 | 0.010 |
Why?
|
| Reoperation | 3 | 1986 | 4303 | 0.010 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1994 | 396 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2000 | 2908 | 0.010 |
Why?
|
| Kidney | 1 | 1987 | 7049 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 1992 | 275 | 0.010 |
Why?
|
| Anesthetics, Inhalation | 1 | 1996 | 574 | 0.010 |
Why?
|
| Medulloblastoma | 1 | 1996 | 678 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 1996 | 748 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1992 | 563 | 0.010 |
Why?
|
| Nitrous Oxide | 1 | 1991 | 166 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1997 | 2642 | 0.010 |
Why?
|
| Homosexuality, Male | 1 | 1998 | 1334 | 0.010 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 1992 | 189 | 0.010 |
Why?
|
| Double-Blind Method | 4 | 1986 | 12330 | 0.010 |
Why?
|
| Physicians | 1 | 2008 | 4591 | 0.010 |
Why?
|
| Anesthesia, Obstetrical | 1 | 1992 | 233 | 0.010 |
Why?
|
| Ploidies | 1 | 1990 | 285 | 0.010 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 1989 | 25 | 0.010 |
Why?
|
| Child of Impaired Parents | 1 | 1993 | 460 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2004 | 7956 | 0.000 |
Why?
|
| Interview, Psychological | 1 | 1992 | 809 | 0.000 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 2916 | 0.000 |
Why?
|
| Personality | 1 | 1991 | 554 | 0.000 |
Why?
|
| Calcitonin | 1 | 1989 | 329 | 0.000 |
Why?
|
| Magnesium Hydroxide | 1 | 1987 | 9 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1994 | 1271 | 0.000 |
Why?
|
| Aluminum Hydroxide | 1 | 1987 | 54 | 0.000 |
Why?
|
| Hepatectomy | 1 | 1991 | 557 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 7409 | 0.000 |
Why?
|
| Demography | 1 | 1991 | 1648 | 0.000 |
Why?
|
| Esthetics | 1 | 1988 | 330 | 0.000 |
Why?
|
| Aneuploidy | 1 | 1989 | 551 | 0.000 |
Why?
|
| Cleft Palate | 1 | 1991 | 589 | 0.000 |
Why?
|
| Muscle Hypotonia | 1 | 1987 | 161 | 0.000 |
Why?
|
| Antifoaming Agents | 1 | 1984 | 2 | 0.000 |
Why?
|
| Curettage | 1 | 1985 | 74 | 0.000 |
Why?
|
| Hypocalcemia | 1 | 1986 | 201 | 0.000 |
Why?
|
| Duodenogastric Reflux | 1 | 1984 | 4 | 0.000 |
Why?
|
| Gastroscopy | 1 | 1986 | 211 | 0.000 |
Why?
|
| Atropine | 1 | 1984 | 244 | 0.000 |
Why?
|
| Neck | 1 | 1989 | 734 | 0.000 |
Why?
|
| Amyloid | 1 | 1989 | 841 | 0.000 |
Why?
|
| Magnesium | 1 | 1987 | 808 | 0.000 |
Why?
|
| Duodenitis | 1 | 1983 | 20 | 0.000 |
Why?
|
| Extremities | 1 | 1989 | 867 | 0.000 |
Why?
|
| Gastric Acid | 1 | 1983 | 99 | 0.000 |
Why?
|
| Warfarin | 1 | 1991 | 1483 | 0.000 |
Why?
|
| Bone Diseases | 1 | 1987 | 418 | 0.000 |
Why?
|
| Head | 1 | 1989 | 924 | 0.000 |
Why?
|
| Castration | 1 | 1983 | 151 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1986 | 1152 | 0.000 |
Why?
|
| Liver Function Tests | 1 | 1984 | 523 | 0.000 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 1986 | 357 | 0.000 |
Why?
|
| Endometrium | 1 | 1985 | 403 | 0.000 |
Why?
|
| Artifacts | 1 | 1991 | 1910 | 0.000 |
Why?
|
| Immunologic Factors | 1 | 1991 | 1588 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1991 | 1514 | 0.000 |
Why?
|
| Postoperative Care | 1 | 1988 | 1471 | 0.000 |
Why?
|
| Creatinine | 1 | 1987 | 1899 | 0.000 |
Why?
|
| Glioblastoma | 1 | 1996 | 3482 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1983 | 603 | 0.000 |
Why?
|
| Myeloproliferative Disorders | 1 | 1986 | 613 | 0.000 |
Why?
|
| Oxygen | 1 | 1991 | 4228 | 0.000 |
Why?
|
| Liver Transplantation | 1 | 1991 | 2333 | 0.000 |
Why?
|
| Psychotic Disorders | 1 | 1993 | 3223 | 0.000 |
Why?
|
| Income | 1 | 1986 | 1876 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1986 | 3425 | 0.000 |
Why?
|
| Depression | 1 | 1992 | 8122 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1991 | 11740 | 0.000 |
Why?
|